DelveInsight Forecasts Saphnelo Market Size and Growth Through 2034

Market research firm DelveInsight has published a new report forecasting the market trajectory for Saphnelo, a therapeutic agent for systemic lupus erythematosus (SLE), up to the year 2034. The analysis covers the drug's sales performance, market share, and anticipated expansion.

Saphnelo, also known as anifrolumab, is recognized as a first-in-class therapy that targets the type I interferon receptor (IFNAR1), a critical component in the pathogenesis of SLE. Clinical trials, including the TULIP program, have demonstrated its efficacy in reducing disease activity and decreasing the reliance on oral corticosteroids among patients.

The report highlights strong early commercial adoption for Saphnelo, which has received approval in over 70 countries. Sales reached approximately $483 million in the first nine months of 2025, suggesting an annualized run rate approaching $600–700 million.

There remains a significant unmet need in SLE management, a chronic condition requiring lifelong treatment. Existing therapies, such as steroids and immunosuppressants, often carry substantial toxicity and may not provide optimal disease control. Consequently, the adoption of targeted biologic therapies like Saphnelo is increasing, with their use rising significantly in patients with moderate to severe SLE.

In February 2026, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) concerning the supplemental application for subcutaneous administration of Saphnelo. The manufacturer is working with the FDA to address the agency's requests. The report's scope includes Saphnelo's current and potential applications across various SLE indications and geographic markets, including the US, EU4, and Japan, through 2034.